


## PHARMACEUTICAL 2017

iBio Inc. Rank 94 of 313







## PHARMACEUTICAL 2017

## iBio Inc. Rank 94 of 313



The relative strengths and weaknesses of iBio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of iBio Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 115% points. The greatest weakness of iBio Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is -43%, being 374% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	23,906
Cost of Goods Sold	0
Intangible Assets	2,092
Liabilities, Current	2,291
Liabilities, Non-Current	0
Other Assets	28
Other Compr. Net Income	-4.0
Other Expenses	0
Other Liabilities	25,265
Other Net Income	-764
Property and Equipment	25,574
Research and Development	3,156
Revenues	948
Selling, General and Administrative Expense	7,685

Output Variable	Value in 1000 USD
Assets	51,600
Liabilities	27,556
Expenses	10,841
Stockholders Equity	24,044
Net Income	-10,657
Comprehensive Net Income	-10,659
Economic Capital Ratio	-43%